Samsung Biologics Co.,Ltd. (207940.KS) stock analysis

In our weekly check, Samsung Biologics Co.,Ltd. is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 18 pass, warnings: 3, red flags: 3.

About Samsung Biologics Co.,Ltd.

Samsung Biologics Co.,Ltd. is a Healthcare company (Biotechnology) based in South Korea, listed on KSC as 207940.KS.

What our checks show for 207940.KS

Red flags

• Operating profit does not cover the interest bill (0.1x): interest is paid from cash or new debt.
• Analysts expect the net margin to shrink by 5.3 points from today's 39.2%.
• Thinly traded (about 63 thousand shares a day): buying and selling can move the price.

Warning signs

• The price is 37.7 times earnings (P/E): the market already pays for a lot of future growth.
• The price swings a lot: 43.5% annual volatility. Expect large ups and downs.
• The stock has fallen as much as 57% from a peak. Would you have held through that?

Strengths

• Net debt is only 0.3x a year of EBITDA: the balance sheet has room.
• The net margin rose by 14.1 points over 5 years, to 39.2%.
• The gross margin is 54.5% and has risen by 4.5 points: pricing power is holding.
• Operating cash flow is 1.26x net profit: the profit arrives as real cash.
• Analysts expect earnings per share to grow about 10.9% a year over the next years.
• Analysts expect revenue to grow about 16.4% a year over the next years.

Similar companies

068270.KS · 196170.KQ

Questions

What grade does Samsung Biologics Co.,Ltd. (207940.KS) have?

In our weekly check, Samsung Biologics Co.,Ltd. is graded B (A to F). Of 24 checks on debt, profit, cash flow and trend: 18 pass, warnings: 3, red flags: 3. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of 207940.KS stock?

This week's biggest flags for Samsung Biologics Co.,Ltd.: Weak interest cover, Margins expected to shrink, Thinly traded. In total 6 of 24 checks show a warning or a red flag.

What does Samsung Biologics Co.,Ltd. do?

Samsung Biologics Co.,Ltd. is a Healthcare company (Biotechnology) based in South Korea, listed on KSC as 207940.KS.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-24

Open the full analysis